US medical device company Equashield through Japanese distributor Tosho has entered into an exclusive agreement with IV tube manufacturer PAL Medical to provide Equashield’s Closed System Transfer Devices (CSTDs) to oncology nurses in Japan.

Post agreement, Tosho will provide PAL Medical with Equashield’s closed IV connectors to develop safer IV sets for oncology nurses administering hazardous chemotherapy drugs.

Commenting on the collaboration with PAL Medical, Jojo Kishimoto – general manager, Tosho said: “Approximately 100 hospital pharmacies in Japan are currently utilizing the EQUASHIELD CSTD for their hazardous drug compounding, due to its superior quality, safety, and ease-of-use.

“Our collaboration with PAL Medical will now provide that same level of protection to oncology nurses in Japan who administer chemotherapy treatments on a daily basis.”

Equashield CSTD now available for oncology nurses in Japan. Photo courtesy of Stuart Miles/Freedigitalphotos.net.

Following reimbursements and official guidelines for CSTD use from the Japanese government, the use of closed systems for compounding chemotherapy medications has increased in recent years.

Adi Shor – VP International Sales, Equashield said: “Japan is becoming a recognized leader in the Asia-Pacific region for safe handling in healthcare settings, thanks to the government support of CSTD implementation through reimbursements.

“We are confident that our strong partnership with Tosho and PAL Medical will continue to help protect increasingly more healthcare workers in the region from the inherent dangers of handling hazardous drugs.”

Equashield’s product portfolio includes Equashield II, a CSTD, and Equashield Pro, a closed system-enabled Automated Pharmacy Compounding System.

Clinically-proven to protect healthcare professionals from hazardous drug exposure, Equashield’s CSTD is said to be deployed faster than any other competing systems.

Equashield II used by hundreds of hospitals and clinics around the world is CE marked and the FDA validated device for preventing microbial ingress for up to a week.

Related posts

• BioMed, University of California open cancer research center in San Diego (0)
• Sumitomo Dainippon Pharma to buy into Roivant Sciences Vants for $3bn (0)
• Maruho, X-Chem collaborate to advance drug discovery (0)
• Valo Therapeutics licenses PeptiENV technology from the University of Helsinki (0)
• MERU clinical trial : AbbVie ends Rova-T program in lung cancer (0)
• Boehringer Ingelheim, MD Anderson to advance new cancer treatments (0)
• Celgene bags Inrebic FDA approval for myelofibrosis (0)
• PAOLA 1 trial results : Lynparza, bevacizumab combo achieves PFS goal in phase 3 trial (0)
• Tagrisso FLAURA trial results : AstraZeneca NSCLC drug significantly improves OS (0)
• ORIC Pharmaceuticals raises $55m to advance cancer resistance drugs (0)

The post Equashield CSTD now available for oncology nurses in Japan appeared first on PharmaNewsDaily.com.